selected publications
-
academic article
- Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution. 2019
- Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. 2019
- Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. 2019
- Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. 2019
- Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. 2018
- Rare and low-frequency coding variants alter human adult height.. Nature. 542:186-190. 2017
- PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.. Journal of medical genetics. 53:800-811. 2016
- Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.. Nature communications. 7:-. 2016
- Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.. Cancer discovery. :-. 2016
- Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk.. Genetic epidemiology. :-. 2015
- Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. :-. 2015
- Identification of six new susceptibility loci for invasive epithelial ovarian cancer. 2015
- Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. 2015
- Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers.. PloS one. 6:-. 2011
- No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.. Gynecologic oncology. -. 2015